Pricing

Cellectar Biosciences Inc (CLRB)

followers ·
Sector:
CONSUMER DISCRETIONARY
Industry:
CONSUMER SERVICES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
James V. Caruso
Employees:
10
100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
(608) 441-8120
    Formally known as:
  • Cellectar Biosci
  • CELLECTAR BIOSCIENCES INC COM STK
  • Novelos Therapeutics, Inc.
  • Novelos Therapeutics, Inc.
Stock Split History
DateRatio
2011-04-11 1:153
2014-06-16 1:20
2016-03-07 1:10
2018-07-17 1:10
2022-07-22 1:10
Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available